Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEquity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Gsk (GLAXF) EBIT (2016 - 2025)

Historic EBIT for Gsk (GLAXF) over the last 17 years, with Q3 2025 value amounting to $3.5 billion.

  • Gsk's EBIT rose 132448.73% to $3.5 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $13.0 billion, marking a year-over-year increase of 3763.55%. This contributed to the annual value of $5.1 billion for FY2024, which is 3873.42% down from last year.
  • According to the latest figures from Q3 2025, Gsk's EBIT is $3.5 billion, which was up 132448.73% from $2.7 billion recorded in Q2 2025.
  • Gsk's EBIT's 5-year high stood at $5.9 billion during Q4 2021, with a 5-year trough of $245.6 million in Q3 2024.
  • For the 5-year period, Gsk's EBIT averaged around $2.7 billion, with its median value being $2.5 billion (2023).
  • As far as peak fluctuations go, Gsk's EBIT tumbled by 9005.3% in 2024, and later surged by 132448.73% in 2025.
  • Quarter analysis of 5 years shows Gsk's EBIT stood at $5.9 billion in 2021, then plummeted by 32.62% to $4.0 billion in 2022, then surged by 32.44% to $5.2 billion in 2023, then decreased by 23.21% to $4.0 billion in 2024, then decreased by 13.09% to $3.5 billion in 2025.
  • Its EBIT was $3.5 billion in Q3 2025, compared to $2.7 billion in Q2 2025 and $2.8 billion in Q1 2025.